CJC-1295 (no DAC) + Ipamorelin

What it is

Combined reference in one lyophilized vial: CJC-1295 without DAC (ModGRF 1–29) and ipamorelin, 5 mg each. Two distinct GH-axis research ligands.

What research explores

• Co-administration of a GHRH analog and a secretagogue
• Combined GH-secretion assays in research models
• Independent quantification of each component
• Stability of lyophilized blends

Studies

Literature is mainly that of each peptide alone; combined studies exist but do not define a clinical standard. Human evidence for the commercial blend is limited.

Reported effects

Report only what each component’s literature describes in models — no commercial synergy claim.

In the literature

Published protocols are model-dependent and typically single-component. CodePept does not publish a combination protocol.

Specs

Format

Lyophilized powder

Quantity

5 mg + 5 mg

Store per the lot sheet, typically refrigerated and protected from light.

Lot: as stated by the manufacturer on the vial

Manufacturer COA — shown when the file exists in the data

Research use

Research use only (RUO). Not for human consumption.